EC Healthcare expects a record-high semi-annual sales volume in first half of FY23 of no less than HK$1.8 billion, Represents no less than 17% Y-o-Y increase
Demonstrate a Notable Recovery Trend and Moving Towards New Normal
HONG KONG, Oct 17, 2022 - (ACN Newswire) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group expects to achieve a record-high semi-annual sales volume from April to September 2022 (the "Reporting Period").
The demand on medical services provided by the Group remains strong and the Group's business demonstrate resilience and momentum backed by the Group's diversified business. The Board expects the Group to achieve a record-high semi-annual overall sales volume of no less than HK$1.8 billion for the Reporting Period, representing a no less than 17% y-o-y increase. The Group expects to achieve a no less than 30% y-o-y increase for medical services sales volume. Sales volume of other services rose by no less than 95% y-o-y, mainly driven by the acquisition of veterinary businesses.
Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, EC Healthcare is always committed to building a diversified healthcare ecosystem to maximize customers' lifetime value. Hong Kong resident now progressively building a herd immunity barrier with a population the cumulative number of reported cases of 5th wave of COVID-19 has reached over 181 million, population completed the third vaccine dose was at approximately 80.2% as of 13 October 2022. The steady recovery in local consumer sentiment is expected to benefit the Group's business. Looking ahead, the Group is optimistic about its business development as the Hong Kong government's pandemic policy stance is heading towards "Normalization" and recently further relaxed quarantine arrangements for inbound travelers, further boosting the market sentiment. The Group will continue to expand its businesses through organic growth as well as mergers and acquisitions, leveraging investment in IT, brand and service to enrich the Group's enclosed diversified ecosystem. The Group will further enhance the resilience and ability to resist economic cyclical changes and further consolidate the healthcare market."
About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.
The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, an advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.
*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021
For further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk / Tim Tin / Sophia Wu Tel: (852) 2136 6952 / 2169 0467 / 3920 7654 / 3920 7645 Fax: (852) 3170 6606 Email: ech@iprogilvy.com
Source: EC Healthcare Sectors: BioTech, Healthcare & Pharm
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
Japan's Telecommunications Carriers Strengthen Disaster Response by Conducting Joint Training for Shared Refueling Stations Jan 28, 2025 17:39 JST
| FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Jan 28, 2025 09:46 JST
| Ogier's milestone Monte win crowns TOYOTA GAZOO Racing one-two Jan 27, 2025 17:24 JST
| Anime Tokyo Station: Let's Enjoy together!! History of Anime Series "OSHI NO KO" Jan 27, 2025 13:00 JST
| hootfolio, Inc., a Provider of Causal Analysis Technology, Launches Business Development Jan 27, 2025 12:01 JST
| Sustainable Shared Transport and Fujitsu launch open platform for joint transportation and delivery in Japan, enhancing logistics efficiency across industries Jan 27, 2025 10:53 JST
| DOCOMO to Exhibit at MWC Barcelona 2025, World's Largest Connectivity Exhibition Jan 24, 2025 17:39 JST
| Hitachi Launches Food Quality Visualization Solution with Time-Temperature Sensing Ink Jan 24, 2025 12:40 JST
| Mitsubishi Heavy Industries Aero Engines and Rolls-Royce Celebrate 20 Years of Collaboration Jan 24, 2025 10:38 JST
| World's First Successful Transmission of Huge Volume Mission Data Using 1.5 micron Optical Inter-Satellite Communication Jan 24, 2025 09:19 JST
| TANAKA PRECIOUS METAL TECHNOLOGIES Develops AgSn TLP Sheet, a Sheet-type Bonding Material for Power Semiconductors Jan 23, 2025 11:00 JST
| MHI Receives Order for 3 New Series Trainsets (12 Cars) for Seibu Railway's Yamaguchi Line Jan 22, 2025 17:27 JST
| Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company Jan 22, 2025 17:18 JST
| Mitsubishi Power Advances Thailand's Energy Development with Completion of 1,400MW Combined Cycle Hin Kong Power Plant Jan 21, 2025 16:24 JST
| DENSO Exhibits at Bharat Mobility Global Expo 2025, New Delhi Jan 20, 2025 20:26 JST
| Hitachi Acquires a Sales and Maintenance Service Company for Large Motors in the United States Jan 20, 2025 15:07 JST
| Suzuki's First BEV "e VITARA" Adopts eAxle Jan 20, 2025 13:58 JST
| Honda Presents the World Premier of BF300 Large-size Outboard Motor at the Dusseldorf Boat Show 2025 Jan 20, 2025 11:36 JST
| TOYOTA GAZOO Racing begins WRC title bid with a legendary challenge Jan 17, 2025 19:53 JST
| Mitsubishi Corporation and JOGMEC Announce Investment in eFuels provider Infinium Jan 17, 2025 14:35 JST
|
More Latest Release >>
|